Metabolon will perform metabolomics on study participants as part of the five-year longitudinal study to improve risk assessment of complications of obesity, supporting greater understanding in patient stratification for the right treatment depending on metabolic profiles.

Metabolomic insights will support the leading science and technology company in advancement of its drug early development programs across therapeutic areas.

Metabolon, Inc. has unveiled a new brand rooted in its 20-year history as a revolutionary leader in metabolomics. The company's corporate mission to "enlighten life and enable a better, healthier world," reflects the unique value and urgency of Precision Metabolomics™ in expanding and accelerating discovery across life sciences research.

Metabolomic insights will support Army’s research into Warfighter health-readiness and optimal performance. Metabolon, Inc., the global leader in metabolomics, has been selected by the U.S. Army Research Institute of Environmental Medicine (USARIEM), to analyze the metabolic profiles of military personnel in a research program being conducted by the Military Nutrition Division.

“We welcome Karl at an exciting time when Metabolon is implementing new strategies to increase our growth and prominence as the biotech partner capable of addressing the most difficult questions in the life sciences through our unmatched approach to metabolomics,” said Rohan Hastie, Ph.D., President and CEO, Metabolon.

Metabolon, Inc. joins forces with three Canadian research groups – The Canadian Frailty Network, the Canadian Longitudinal Study of Aging (CLSA) and the McMaster Institute for Research on Aging (MIRA) – to discover the frailty biomarkers that may shed light on why some people become frail, determine the severity of frailty and what can be done to help avoid the condition.

The U.S. Department of Veterans Affairs (VA) has selected the Company through its alliance with AKESOgen, a leader in genomics, to perform large-scale metabolomic profiling on biological samples from U.S. veterans as part of the Million Veteran Program (MVP).

Type 2 diabetes, which affects over 30 million individuals at an annual cost of over $300 billion in the United States alone, results when the body’s normal metabolic response to a meal is impaired.  This suggests that measuring changes in metabolites using a technology called metabolomics should provide clues into how the disease develops and how it can be treated.